REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpectra (di/ S) Regulatory News (SPSC)

Share Price Information for Spectra (di/ S) (SPSC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 260.00
Bid: 220.00
Ask: 300.00
Change: 0.00 (0.00%)
Spread: 80.00 (36.364%)
Open: 260.00
High: 260.00
Low: 260.00
Prev. Close: 260.00
SPSC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Share Options

28 Mar 2022 07:00

RNS Number : 1537G
Spectra Systems Corporation
28 March 2022
 

Spectra Systems Corporation("Spectra" or the "Company")

Grant of Share Options

Spectra Systems Corporation, a leader in machine-readable high speed banknote authentication, brand protection technologies and gaming security software announces that in accordance with the Company's 2007 Incentive Compensation Plan and the recommendation of the Compensation Committee, the Board granted options ("Options") over 531,000 shares of Common Stock ("Shares") to Corporate Officers and other employees of the Company.

Since the Company was admitted to trading on AIM on 25 July 2011, options issued over a total of 3,600,667 Shares remain outstanding, including this grant of Options, and 422,615 Shares have been issued as a result of option exercises. The aggregate total of 4,023,282 represents 8.9 percent of Spectra's current issued shares of common stock. Additionally, 5,403,649 pre-admittance options have expired since 25 July 2011.

The Options, which expire on 25 March 2032, have an exercise price of 150.50 pence per Share and vest over three years, one-third per year.

The grant of the Options is designed to align the interests of key employees of the Company with those of shareholders and to promote the retention of those individuals.

Details of the number of shares over which Options have been granted to Persons Discharging Management Responsibilities of the Company and their resultant interests are set out below:

Name

Title

New Options

Existing Options

Total Options

Total Shares

Nabil Lawandy

CEO

150,000

1,881,063

2,031,063

2,247,736

Brian McLain

CFO

120,000

212,000

332,000

38,000

 

Donald Stanford, Chairman of the Compensation Committee commented: "We believe that this grant of options, which accords with our policy as announced at the time of our IPO in 2011, provides an opportunity for our key employees to benefit from significantly growing the value of our company, thereby aligning their interests with shareholders." 

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

Enquiries:

Spectra Systems Corporation

 

Dr. Nabil Lawandy, Chief Executive Officer

Tel: +1 (0) 401 274 4700

 

 

WH Ireland Limited (Nominated Adviser and Broker)

 

Chris Fielding (Head of Corporate Finance)

Andrew de Andrade (Executive, Corporate Finance)

Tel: +44 (0) 20 7220 1650

 

 

Allenby Capital Limited (Joint Broker)

 

Nick Naylor/James Reeve (Corporate Finance)

Tel: +44 (0) 20 3328 5665

Amrit Nahal (Sales and Corporate Broking)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHMZGZFLNNGZZM
Date   Source Headline
14th Jun 20217:00 amRNSAnnual General Meeting Update
17th May 20215:12 pmRNSShare Buy-Back
7th May 20214:49 pmRNSShare Buy-Back
6th May 20212:58 pmRNSShare Buy-Back
4th May 20215:51 pmRNSPosting of Annual Report and Accounts, AGM Notice
26th Apr 20211:45 pmRNSExercise of Options
22nd Apr 20217:00 amRNSNew Lottery Contracts
21st Apr 20217:00 amRNSEnhanced sensor capability contract
19th Apr 20211:46 pmRNSExercise of Options
8th Apr 20217:00 amRNSAllowance of Banknote Disinfection Patent
1st Apr 20213:29 pmRNSExercise of Options and Director/PDMR Shareholding
22nd Mar 20217:35 amRNSAudited Results for the 12 months ended 31 Dec 20
10th Feb 20217:00 amRNSExercise of Options
9th Feb 20212:11 pmRNSAppointment of Director
2nd Feb 20217:00 amRNSSecond phase of contract for sensor development
1st Feb 20213:33 pmRNSExercise of Options
20th Jan 20217:00 amRNSExercise of Options and Director/PDMR Shareholding
5th Jan 20214:02 pmRNSDirectorate
5th Jan 20217:00 amRNSShare Buy-Back
14th Dec 20207:01 amRNSTwo Lottery Renewals
14th Dec 20207:00 amRNSAcquisition of interest - Solaris BioSciences, Inc
21st Oct 20209:06 amRNSSecond Price Monitoring Extn
21st Oct 20209:01 amRNSPrice Monitoring Extension
21st Oct 20207:00 amRNSContract with a Central Bank
14th Oct 20205:27 pmRNSHolding(s) in Company
6th Oct 20207:00 amRNSRemoval of Regulation S Restrictions
11th Sep 20204:34 pmRNSExercise of Options and Director/PDMR Shareholding
10th Sep 20207:00 amRNSExercise of Options and Director/PDMR Shareholding
7th Sep 20207:00 amRNSInterim Results for the Six Months 30 June 20
25th Aug 20204:11 pmRNSHolding(s) in Company
15th Jul 20206:25 pmRNSDirector Dealings
9th Jul 20207:00 amRNSContract with a Major Central Bank
26th Jun 20207:00 amRNSShare Buy-Back
25th Jun 20207:00 amRNSShare Buy-Back and Removal of Reg S Restrictions
16th Jun 20203:23 pmRNSShare Buy-Back
10th Jun 20207:00 amRNSAsian Central Bank Contract Update
26th May 20207:00 amRNSDirector Dealings
15th May 20205:24 pmRNSExercise of Options and Removal of Regulation S
30th Apr 20208:51 amRNSPosting of Annual Report and Accounts
3rd Apr 20204:56 pmRNSShare Buy-Back and Removal of Reg S Restrictions
23rd Mar 202012:37 pmRNSAudited Results
16th Mar 20201:59 pmRNSHolding(s) in Company
9th Mar 20204:41 pmRNSPrice Monitoring Extension
21st Feb 20207:00 amRNSShare Buy-Back
11th Nov 20193:30 pmRNSHolding(s) in Company
30th Oct 20191:39 pmRNSHolding(s) in Company
16th Oct 20197:00 amRNSHolding(s) in Company
25th Sep 20192:59 pmRNSHolding(s) in Company
24th Sep 20197:00 amRNSInterim Results
17th Sep 20197:00 amRNSFunding Approval - G7 Central Bank

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.